Coffee and In-vivo Oxidative Stress

This study has been completed.
Sponsor:
Collaborator:
Mondelēz International, Inc.
Information provided by (Responsible Party):
W.J. Pasman, TNO Quality of Life
ClinicalTrials.gov Identifier:
NCT00868205
First received: March 23, 2009
Last updated: February 27, 2012
Last verified: February 2012
  Purpose

Food and beverage intake that leads to a decrease in the level of in vivo markers of oxidative stress indicates that such foods and beverages act as antioxidants (AOX) in humans. Coffee drinking at a high level (> 900 ml/day) for a short period of time (1 week) has been shown to reduce DNA oxidative damage—as indicated by a decrease in the level of percent tail DNA (%T)— in study populations comprised mainly of young adults aged < 30 years. It is not clear whether such findings remain present over a longer period of time, and to extend such findings across a population that is more representative of European adults who consume common daily intakes of coffee, which is a low-to-moderate daily intake level (< 750 ml/day). As such, the investigators propose to determine the effect of drinking 3 and 5 cups of coffee per day (equivalent to 450 and 750 ml per day, respectively) for 8-weeks on markers of in vivo oxidative stress relative to control in a population of healthy adults free of chronic diseases aged 35 to 65 years. To ensure that overall health is considered, the investigators will also evaluate the effect on markers of cardiovascular health, inflammation, and glycemic control.


Condition Intervention Phase
Healthy
Dietary Supplement: Coffee consumption
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: The Relationship Between Short- and Mid-term Intake of Coffee on in Vivo Levels of Oxidative Stress Parameters in Healthy Adults.

Resource links provided by NLM:


Further study details as provided by TNO:

Primary Outcome Measures:
  • DNA oxidative damage (Comet assay, %T) [ Time Frame: week 0, 4, 5,6,9 and 13 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Lipid oxidative damage (8-isoprostane in urine) [ Time Frame: week 5,6,9,13 ] [ Designated as safety issue: No ]

Estimated Enrollment: 180
Study Start Date: March 2009
Study Completion Date: March 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: low coffee dose
3 cups of coffee daily for 8 weeks
Dietary Supplement: Coffee consumption
3 or 5 cups of coffee daily for eight weeks
Experimental: high coffee dose
5 cups of coffee daily for eight weeks
Dietary Supplement: Coffee consumption
3 or 5 cups of coffee daily for eight weeks
No Intervention: Control
Consumption of water instead of coffee daily for eight weeks

Detailed Description:

Objective: The main objective of the present study is to determine the short- and mid-term effects of a coffee, on oxidative stress parameters in humans.

Study design: randomized, placebo-controlled, investigator-blinded, 3-arm parallel Study population: 168 apparently healthy volunteers: males and females aged >=35 and <= 65 years.

Intervention: The treatments consist of daily consumption of either:

Treatment 1: 0.45 L coffee (3 cups) and 0.30 L bottled water daily or; Treatment 2: 0.75 L coffee (5 cups) daily or; Treatment 3: 0.75 L water daily Duration of the treatment intervention is 8 weeks. Before the intervention period starts, a run-in period of five weeks where all subjects maintain their low antioxidant diet (Dutch average) is conducted by all subjects in order to standardize the antioxidant intake of the subjects.

Main study parameters/endpoints: Mean level of %T as a measure of DNA oxidative damage at week 8. Secondary outcome is the mean level of 8-isoprostane in 24 hr urine.

  Eligibility

Ages Eligible for Study:   35 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy as assessed by the

    • health and lifestyle questionnaire, (P8353 F02; in Dutch)
    • results of the pre-study laboratory tests
  2. Males and females aged >= 35 and <= 65 years at Week 01 of the study
  3. Body Mass Index (BMI) >= 20.0 but <= 34.9 kg/m2
  4. Blood pressure (automated measurement at site): systolic blood pressure <= 139 mm Hg and diastolic blood pressure <= 89 mm Hg
  5. Fasting glucose <= 6.9 mmol/L
  6. No smoking or moderate smoking of 1 to 19 cigarettes per day, with the proportion of smokers and nonsmokers representative of the European adult population aged 35-65 years
  7. Normal European eating habits as assessed by P8353 F02. Fruit and vegetable consumption at a level representative or less for the European population as assessed by P8353 F06
  8. Habitual caffeinated coffee drinker who consumes > 1 cup per day on at least 5 days per week as assessed by P8353 F02
  9. Voluntary participation
  10. Having given written informed consent
  11. Willing to comply with the study procedures
  12. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
  13. Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

Exclusion Criteria:

Subjects with one or more of the following characteristics will be excluded from participation:

  1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
  2. Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
  3. Having a history of medical or surgical events that may significantly affect the study outcome (including cardiovascular disease or hypertension at repeated measurements, hypercholesterolemia, hyperglycaemia, kidney or liver disease, cancer, mental illness) based on the health questionnaire
  4. Hypertension as indicated by a systolic BP >= 140 mm Hg or a diastolic BP >= 90 mm Hg
  5. Hypercholesterolemia as indicated by a fasting LDL-cholesterol >= 4.9 mmol/L at a single screening visit or the use of anti-hypercholesterolemia drugs
  6. Diabetes as indicated by a fasting blood glucose >= 7.0 mmol/L at a single screening visit
  7. Having (a history of) (severe) gastro-intestinal complaints
  8. Using medication for high blood pressure, high cholesterol level, gastro-intestinal complaints, or antidepressants. With the exception of medication for heartburn
  9. Not willing to give up the use of coffee, tea, dark chocolate (and foods/beverages containing dark chocolate), vitamin supplements, mineral supplements, herbal products (food, beverage, or supplements), antioxidant dietary supplements, omega-3 fatty acid supplements including flaxseed oil and fish oil supplements, red wine or rose wines, port, sherry, or specific fortified foods
  10. Not willing to give up the consumption of coffee beans as food or in foods or the consumption of coffee or espresso in foods (e.g. Tiramisu)
  11. The use of any non-study caffeinated/decaffeinated coffee beverage or caffeinated/decaffeinated espresso-based beverage (espresso, cappuccino, latte, frappuccino, or frappe
  12. Alcohol consumption > 28 units/week for males and > 21 units/week for females
  13. Eating lots of fruit and vegetables (i.e. more than 400 gram vegetables per day and more than 4 servings of fruit per day at screening and during the study. This is twice that of the Dutch dietary recommendations for fruit and vegetable intake)
  14. Changing smoking habits (> 5 cigarettes per day)
  15. Exercising heavily (> 7 hours/week)
  16. Not willing to give up supplement (antioxidant containing) use (to be specified)
  17. Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
  18. Reported slimming or medically prescribed diet
  19. Reported vegan, vegetarian or macrobiotic
  20. Recent blood donation (<1 month prior to the start of the study)
  21. Not willing to give up blood donation during the study.
  22. Pregnant or lactating or wishing to become pregnant in the period of the study
  23. Personnel of TNO Quality of Life, their partner and their first and second degree relatives
  24. Not having a general practitioner
  25. Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868205

Locations
Netherlands
TNO Quality of Life
Zeist, Utrecht, Netherlands, 3700 AJ
Sponsors and Collaborators
TNO
Mondelēz International, Inc.
Investigators
Principal Investigator: Wilrike Pasman, PhD TNO
  More Information

Additional Information:
Publications:
Responsible Party: W.J. Pasman, TNO, Zeist, The Netherlands, TNO Quality of Life
ClinicalTrials.gov Identifier: NCT00868205     History of Changes
Other Study ID Numbers: P8353
Study First Received: March 23, 2009
Last Updated: February 27, 2012
Health Authority: The Netherlands: Centrale Commissie Medisch Onderzoek

Keywords provided by TNO:
oxidative stress
Comet assay
antioxidants

ClinicalTrials.gov processed this record on August 28, 2014